课题基金 / 基金详情

STUDIES ON THE TREATMENT AND CHARACTERISTICS OF THORACIC MALIGNANCIES

STUDIES ON THE TREATMENT AND CHARACTERISTICS OF THORACIC MALIGNANCIES
胸部恶性肿瘤的治疗及特点研究
批准号:
2464450
负责人:
H I PASS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

H I PASS的其他基金

相关文献

中文摘要
翻译
我们的部门已经制定了治疗和研究的协议, 胸部恶性肿瘤,包括间皮瘤,转移性疾病, 肺癌和食道癌 在进行了一项I期试验后, 胸膜疾病的光疗(Ann Surg Oncol 1994; 1:28-37)和 免疫化疗(顺铂,干扰素, 他莫昔芬:CIT)治疗恶性胸膜间皮瘤(MPM)(Ann Surg Oncol 1995;2:214-220),一项III期试验正在进行中, 减积手术,术中光动力治疗,术后 CIT至最大减积手术和术后CIT。 这个程序有 自1993年7月以来,累计63例MPM患者。48名患者接受治疗 (15患者不能进行减容)。此项目现已停止应计 由于胸部肿瘤科主任的预期变化。中位生存 48名患者的手术时间为14个月,而未膨胀的患者为7个月。 患者在存活率或至 两组之间的复发率。 基准调查导致 间皮瘤的临床试验中, 20种新的细胞系,正在评估其生长因子机制 包括胰岛素生长因子和CD 44的存在, 透明质酸结合受体 我们也在扩大我们的 SV 40等DNA病毒与MPM关系的研究 致癌作用,在我们最初的描述之后,我们的人类MPM的60% 样本中有T抗原的DNA 这些调查包括分析 血清T抗原抗体,羧基PCR扩增 T抗原DNA末端和SV 40增强子启动子区 人MPM和T-抗原-p53关系。 延迟肿瘤发展, 已经报道了用反义技术靶向IGF-1受体。 对于18例肺转移患者, 肺灌注人重组肿瘤坏死因子, 证明了这种细胞因子检测方法的可行性和安全性 给药剂量高达9 mg。 干扰素的新辅助试验, 顺铂,5-FU和亚叶酸已经完成了评估, 食管内超声的实用性和食管的应答率 carcinoma.
英文摘要
Our Section has developed protocols for the treatment and study of thoracic malignancies including mesothelioma, metastatic disease to the lungs, and esophageal cancer. After performing a Phase I trial of phototherapy for pleural disease (Ann Surg Oncol 1994; 1:28-37) and a Phase II trial of immunochemotherapy (cisplatin, interferon, and tamoxifen: CIT) for malignant pleural mesothelioma(MPM) (Ann Surg Oncol 1995;2:214-220), a Phase III trial has been ongoing which compares maximal debulking surgery, intraoperative photodynamic therapy, and postoperative CIT to maximal debulking surgery and postoperative CIT. This program has accumulated 63 patients with MPM since July 1993. 48 patients have treated (15 patients could not be debulked). This project is now closed to accrual due to the anticipated change in Head, Thoracic Oncology. Median survival for the 48 patients is 14 months, compared to 7 months for the undebulked patients. There are no significant differences in survival or time to recurrence between the two groups. Benchwork investigations resulting from the clinical trials in mesothelioma have included the development of 20 new cell lines, which are being evaluated for growth factor mechanisms including the insulin growth factors, and the presence of CD44, the hyaluronic acid binding receptor. We are also expanding our investigations into the relationship of DNA viruses such as SV40 and MPM carcinogenesis, after our original description that 60% of our human MPM specimens had DNA for T-antigen. These investigations include analysis of sera for antibodies to T-antigen, PCR amplification of the carboxyl terminal end of T-antigen DNA and enhancer promoter region for SV40 from human MPM, and T-antigen-p53 relationships. Delayed tumor development by targeting the IGF-1 receptor with antisense technology has been reported. For 18 patients with pulmonary metastases, a Phase I trial of isolated lung perfusion with human recombinant tumor necrosis factor has demonstrated the feasibility and safety of this method of cytokine delivery for doses up to 9 mg. A neoadjuvant trial of interferon, cisplatinum, 5-FU, and leucovorin has been completed evaluating the utility of endoesophageal ultrasound, and response rates in esophagageal carcinoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDIES OF PHOTOTHERAPY FOR THORACIC MALIGNANCIES
  • 批准号:
    3916630
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H I PASS
  • 依托单位:
STUDIES ON THE TREATMENT AND CHARACTERISTICS OF THORACIC MALIGNANCIES
  • 批准号:
    3774606
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H I PASS
  • 依托单位:
STUDIES OF PHOTOTHERAPY FOR THORACIC MALIGNANCIES
  • 批准号:
    3874452
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H I PASS
  • 依托单位:
STUDIES OF PHOTOTHERAPY FOR THORACIC MALIGNANCIES
  • 批准号:
    3939564
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H I PASS
  • 依托单位: